Your browser doesn't support javascript.
loading
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Ledermann, J A; Matias-Guiu, X; Amant, F; Concin, N; Davidson, B; Fotopoulou, C; González-Martin, A; Gourley, C; Leary, A; Lorusso, D; Banerjee, S; Chiva, L; Cibula, D; Colombo, N; Croce, S; Eriksson, A G; Falandry, C; Fischerova, D; Harter, P; Joly, F; Lazaro, C; Lok, C; Mahner, S; Marmé, F; Marth, C; McCluggage, W G; McNeish, I A; Morice, P; Nicum, S; Oaknin, A; Pérez-Fidalgo, J A; Pignata, S; Ramirez, P T; Ray-Coquard, I; Romero, I; Scambia, G; Sehouli, J; Shapira-Frommer, R; Sundar, S; Tan, D S P; Taskiran, C; van Driel, W J; Vergote, I; Planchamp, F; Sessa, C; Fagotti, A.
Afiliação
  • Ledermann JA; Department of Oncology, UCL Cancer Institute, University College London, London, UK. Electronic address: clinicalguidelines@esmo.org.
  • Matias-Guiu X; CIBERONC, Madrid; Department of Pathology, Hospital Universitari Arnau de Vilanova, IRBLLEIDA, University of Lleida, Lleida; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Barcelona, Spain. Electronic address: admin@esp-pathology.org.
  • Amant F; Department of Gynaecologic Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Department of Gynecology, Center for Gynecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Concin N; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria; Department of Gynaecology and Gynaecologic Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany.
  • Davidson B; Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Fotopoulou C; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
  • González-Martin A; Department of Medical Oncology and Program in Solid Tumours-Cima, Cancer Center Clínica Universidad de Navarra, Madrid, Spain.
  • Gourley C; Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
  • Leary A; Department of Medicine, Institut Gustave Roussy, Villejuif, France.
  • Lorusso D; Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; Department of Woman, Child and Public Health, Catholic University of Sacred Heart, Rome, Italy.
  • Banerjee S; The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK.
  • Chiva L; Department of Gynaecology and Obstetrics, Cancer Center Clínica Universidad de Navarra, Navarra, Spain.
  • Cibula D; Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Colombo N; Department of Gynecologic Oncology, Istituto Europeo di Oncologia IRCCS, Milan; Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
  • Croce S; Department of Biopathology, Bergonié Institut, Bordeaux, France.
  • Eriksson AG; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Gynecologic Oncology, Division of Cancer Medicine, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
  • Falandry C; Institute of Aging, Hospices Civils de Lyon, Lyon; CarMeN Laboratory, INSERM U1060/Université Lyon 1/INRAE U1397/Hospices Civils Lyon, Pierre-Bénite, France.
  • Fischerova D; Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Harter P; Department of Gynaecology and Gynaecologic Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Germany.
  • Joly F; GINECO Group, Department of Medical Oncology, Centre François-Baclesse, University of Caen Normandy, Caen, France.
  • Lazaro C; Hereditary Cancer Program, Catalan Institute of Oncology (ICO-IDIBELL-CIBERONC), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Lok C; Department of Gynecology, Center for Gynecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Mahner S; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Germany; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich.
  • Marmé F; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group, Germany; Department of Obstetrics and Gynecology, University Hospital Mannheim, Mannheim; Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
  • Marth C; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria.
  • McCluggage WG; Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK.
  • McNeish IA; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
  • Morice P; Department of Gynecologic Surgery, Gustave Roussy Cancer Campus, Villejuif, France.
  • Nicum S; Department of Oncology, UCL Cancer Institute, University College London, London, UK.
  • Oaknin A; Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona.
  • Pérez-Fidalgo JA; Department of Medical Oncology, Hospital Clínico Universitario - INCLIVA, CIBERONC, Valencia, Spain.
  • Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori di Napoli, IRCCS Fondazione Pascale, Napoli, Italy.
  • Ramirez PT; Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, USA.
  • Ray-Coquard I; Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard, Lyon, France.
  • Romero I; Department of Medical Oncology, Instituto Valenciano Oncologia, Valencia, Spain.
  • Scambia G; Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; Department of Woman, Child and Public Health, Catholic University of Sacred Heart, Rome, Italy.
  • Sehouli J; North-Eastern German Society of Gynecological Oncology (NOGGO), Berlin; Department of Gynecology with Center for Oncological Surgery, Charité Berlin University of Medicine, Berlin, Germany.
  • Shapira-Frommer R; Sheba Medical Center, Ramat Gan, Israel.
  • Sundar S; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham; Pan Birmingham Gynaecological Cancer Centre, City Hospital, Birmingham, UK.
  • Tan DSP; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; National University of Singapore (NUS) Centre for Cancer Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Cancer Science Institute, National University of Sing
  • Taskiran C; Department of Gynecologic Oncology, School of Medicine, Koç University, Istanbul, Turkey.
  • van Driel WJ; Department of Gynecology, Center for Gynecological Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Vergote I; Department of Gynaecologic Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
  • Planchamp F; Institut Bergonié, Bordeaux, France.
  • Sessa C; Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Fagotti A; Division of Gynecologic Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; Department of Woman, Child and Public Health, Catholic University of Sacred Heart, Rome, Italy. Electronic address: guidelines@esgo.org.
Ann Oncol ; 35(3): 248-266, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38307807
ABSTRACT
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Limite: Female / Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Limite: Female / Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article